Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

Exclusion Criteria

• •Known history of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib.
• •Presence of severely impaired renal function defined by estimated creatinine clearance \< 15 mL/min measured or calculated by Cockcroft-Gault equation or calculated by the updated bedside Schwartz equation. Participants must not be receiving CRRT or intermittent hemodialysis at screening.
• •In the opinion of the investigator, unlikely to survive for \> 24 hours from randomization.
• •Suspected active uncontrolled bacterial, fungal, viral, or other infection (besides COVID-19).
• •Currently receiving ECMO.
• •Participant may not be sharing a ventilator, or co-ventilating, with any other patient.
• •Treatment with anti-IL-6, IL-6R, IL-1RA, IL-1β, or GM-CSF antagonists, or a BTK inhibitor, within 7 days of randomization.
• •Treatment with a JAK inhibitor within 30 days of randomization.
• •Participants who are on long-term use of antirejection or immunomodulatory drugs.
• •Pregnant or nursing (lactating) women.